[ad_1]
Klinicians in Japan are preparing to implant manufactured neuronal cells from "reprogrammed" stem cells in the brain. people with Parkinson's disease. This is only the third clinical application of induced pluripotent stem cells (iPS), which are developed by reprogramming cells of body tissues such as the skin to return to an embryonic state, from which they can transform into dies. Other types of cells. [19659005LeschercheursontutilisécettetechniquepourgénérerdesprécurseursdesneuronesquiproduisentladopamineunneurotransmetteurquidégénèreetmeurtchezlespersonnesatteintesdelamaladiedeParkinsonLesmédecinsdel'hôpitaluniversitairedeKyotoinjecteront5millionsdecescellulesprécurseursdanslecerveaudeseptpersonnesatteintesdelamaladieParcequelesneuronesproducteursdedopaminesontimpliquésdanslescompétencesmotriceslespersonnesatteintesdelamaladieéprouventgénéralementdestremblementsetdesmusclesraidesLesparticipantsserontobservéspendantdeuxansaprèslatransplantation
L & # 39; a leader in the & # 39; test the scientific stem cell Jun Takahashi Research Center and & # 39; application of iPS cells in Kyoto, demonstrated in 2017 that the precursor cells differentiate into dopamine. neurons in monkeys who had a version of the disease. 1 .
In 2014, ophthalmologist Masayo Takahashi – Takahashi's wife – at the RIKEN Center for Developmental Biology in Kobe developed an iPS-based therapy to treat retinal disease. And in May, a team from Osaka University was given permission to use cells created from iPS cells to treat heart disease.
Sign up for the daily newsletter Nature Briefing
Science questions and why, handpicked from Nature and other publications worldwide.
Enter
Source link